昌吉挂号男科医院昌吉哪些医院流产好,昌吉尿道炎去哪个医院好,人流昌吉哪家医院好,昌吉不要孩子花费,昌吉勃起障碍的分类,昌吉做一个全面的妇科检查需要多少钱,做流产的医院昌吉

XICHANG, Sichuan, June 21 (Xinhua) -- China successfully launched a new communication satellite, the Zhongxing-10, from its Xichang Satellite Launch Center in southwest Sichuan Province on early Tuesday.The satellite, carried by a Long March-3B rocket carrier, blasted off from the center at 0:13 a.m., said a statement from the center.According to statistics from the control center, the satellite successfully separated from its carrier rocket and entered Earth's orbit as scheduled, 26 minutes after being launched.The Zhongxing-10 was designed and manufactured by the China Academy of Space Technology under the China Aerospace Science and Technology Corporation.The satellite will provide communication, broadcasting and data transmission services for users in China and the Asia-Pacific region. It will replace the Zhongxing-5B satellite, which was launched in 1998.The launch was the 138th mission for the Long March carrier rocket series.

VIENNA, Aug. 11 (Xinhua) -- Austrian researchers have developed a method of using fungi and produced enzymes to split Polyethylene Terephthalate (PET) material into their initial state, enabling the recovery of all individual components, said the Austrian Center of Industrial Biotechnology (ACIB) Thursday in a press release.Enzyme is a special protein that acts as biological catalyst, for example, bacteria and fungi in the nature can break down long chain molecules.Researchers from the Technical University of Graz, the Technical University of Vienna and the Agricultural University of Vienna jointly found that efficient enzymes are capable to break and split PET into small fragments.With different methods, the researchers forced the fungi to overproduce their precious "split-tools" after they are modified and improved by genetic engineering.Through the new method developed by the ACIB, it is now possible to decompose the PET polymer to its initial monomers with high product quality and from this to produce new high-quality materials again.This circuit avoids waste and thus saves resources and is friendly to the environment, said Geog Guebitz, head of the Research Department on Enzymes and Polymers in the ACIB.He further explained that the ACIB has established a partnership with some industrial enterprises to carry out application experiments. From the current splitting time of 24 hours, the researchers expect to shorten the whole process to "a few hours," he added.PET is a common plastic material in the polyester family, widely used in the textile industry. PET film is mainly used in electrical insulation materials, which can be also used for production of film, X-ray films and computer taps, even to produce plastic bottle and other blow molding products.

SAN FRANCISCO, June 28 (Xinhua) -- Microsoft on Tuesday launched its cloud service Office 365, which was the software giant's answer to competing products from Google and other companies.The service includes on-line versions of Word, PowerPoint, Excel, Outlook and other Office applications, as well as Microsoft 's communication and collaboration tools such as Exchange, SharePoint and Lync.It will allow users to work on files and documents at the same time using instant messaging and video-conferencing."Where does Office meet the cloud? It's Office 365, the absolute best productivity and collaboration service for business around the world," Microsoft CEO Steve Ballmer said at a webcast event.Microsoft said that Office 365 is now available in 40 markets with choices for small and big businesses ranging from 2 to 27 U.S. dollars per user per month.Office 365 will compete directly with the web-based Google Apps, which Google sells for 50 dollars per user per year.Microsoft's service was introduced in beta last year and the company said response was enthusiastic with more than 200,000 organizations signed up and began testing it in a few months."With a few clicks, Office 365 levels the playing field, giving small and midsize businesses powerful collaboration tools that have given big businesses an edge for years," Ballmer said in a statement.

BEIJING, July 11 (Xinhuanet) -- Gay and bisexual men account for around one in every three new cases of HIV in China, according to the latest official statistics released by the Ministry of Health.About 5 percent of the group - officially termed men who have sex with men, or MSM - are living with the virus, which is a rate that is 88 times higher than the national HIV prevalence rate of 0.057 percent.The problem is particularly acute in large urban centers, with the prevalence rate in some southwestern cities reaching almost 20 percent.However, the statistics also show that less than half of all gay and bisexual men have access to HIV screening, while about 15 percent of those who are infected are not receiving treatment."Cities are at the heart of China's development and progress and must remain at the forefront of its HIV response," said Michel Sidibe, executive director of the Joint United Nations Programme on HIV/AIDS (UNAIDS), during a workshop about the HIV impact on MSM on Saturday in Chengdu, capital of Southwest China's Sichuan province."Through bold action cities can lead the way to achieving the UNAIDS vision of zero new HIV infections, zero discrimination and zero AIDS-related deaths," he said, according to a UNAIDS news release. "We hope that over the next year, many more Chinese cities will implement MSM strategies."Almost 10 percent of gay and bisexual men in Chengdu are HIV-positive, according to Yang Xiaoguang, director of the city's health bureau. He agreed with Sidibe that cities have a crucial role to play in AIDS prevention and added: "By working to build a strong, multi-sector response in Chengdu, with meaningful community participation, we can scale-up coverage of prevention, treatment and care services among MSM and halt the spread of HIV."During the workshop, senior Chinese health officials, representatives from civil societies and other delegates discussed a new five-year strategy that increases coverage of HIV prevention and treatment for the MSM population and promotes the participation of community organizations.Government estimates put China's population of gay men at between 5 and 10 million, although Zhang Beichuan, a leading expert on HIV at Qingdao University, puts the number closer to 30 million.Tong Ge, coordinator of China's MSM Health Forum, noted the importance of ensuring strong cooperation between the government and society."By building on the experiences of cities like Chengdu, which already have well developed AIDS responses, we can help promote multi-sector collaboration on an equal, orderly basis and strengthen the response to HIV nationwide," he said. "The next step will be to implement similar strategies in other cities nationwide."Chengdu's new strategy underscores the critical role community organizations can play in reaching MSM and other populations at a higher risk of infection, experts at the workshop said.In 2009, China had an estimated 740,000 people living with HIV/AIDS, according to UNAIDS statistics.

LOS ANGELES, June 5 (Xinhua) -- U.S. researchers have developed two new drugs that can prolong the lives of patients with advanced melanoma, it was announced on Sunday.Research on both drugs was presented at the on-going annual meeting of the American Society of Clinical Oncology in Chicago, according to HealthDay News.This is the first big news in years for treatment of melanoma, one of the deadliest forms of skin cancer and one that is notoriously difficult to treat, let alone cure, the report said.The first treatment, vemurafenib, inhibits a gene mutation harbored in half of all melanoma patients, but is not yet approved by the U.S. Food and Drug Administration.The other drug, Yervoy (ipilumumab), is an immune system therapy that won approval in March."The March FDA approval of ipilumumab (Yervoy) was the first new drug approval for melanoma in 13 years," said Tim Turnham, executive director of the Melanoma Research Foundation.The two drugs were developed by researchers at Memorial Sloan- Kettering Cancer Center in New York City, the report said."This is really a huge step toward personalized care in melanoma," Dr. Paul Chapman, lead author of the first study and the attending physician in the melanoma/sarcoma service at Memorial Sloan-Kettering, said in a statement. "This (vemurafenib) is the first successful melanoma treatment tailored to patients who carry a specific gene mutation in their tumor, and could eventually become one of only two drugs available that improves overall survival in advanced cancers.""Having two trials that show a benefit in survival in patients with melanoma, both of these in first-line settings -- we weren't here just a few years ago," said Dr. Stephen Hodi, director of the Melanoma Center at Dana Farber Cancer Institute in Boston. "These are huge, paradigm-shifting results for the field."In the vemurafenib trial, sponsored by the drug's makers, researchers randomly assigned 675 patients with advanced, inoperable melanoma to receive either the chemotherapy drug dacarbazine or vemurafenib. Vemurafenib targets the V600E mutation in the BRAF gene.At the three-month mark, patients taking vemurafenib were 63 percent less likely to die and 74 percent less likely to die or see their cancer return, compared to patients taking dacarbazine alone.Few patients had side effects in the vemurafenib group, although some did develop squamous cell carcinoma, a less dangerous form of skin cancer.This is the first drug that has been proven superior to chemotherapy in this group of hard-to-treat patients, the researchers said."There was such a substantial benefit that we recommended that patients cross over," Chapman said at a Sunday news briefing. "It' s unprecedented to report a trial this early. The median follow-up time was three months." Yet the differences between the two groups became evident almost immediately.Dr. Lynn Schuchter, co-moderator of the briefing and division chief of hematology-oncology at Abramson Cancer Center of the University of Pennsylvania in Philadelphia, said symptoms subsided in some patients almost immediately, enabling them to cut back on pain medication in just 72 hours."The median time to progression with dacarbazine was 1.6 months versus three months with vemurafenib, which is a huge difference," said Chapman.In the second study, about 500 patients were randomly picked to receive Yervoy plus dacarbazine or dacarbazine alone.Those taking both drugs lived a median of 11.2 months compared to 9.1 months for those taking dacarbazine alone. Time to recurrence of disease was about the same for both groups: 2.8 months and 2.6 months, respectively.Almost half of those taking the combination therapy were alive after one year, compared to 36.3 percent in the other group. After two years, the rates were 28.5 percent and 17.9 percent, respectively.By three years out, 20.8 percent of those in the combination group were alive compared with 12.2 percent of those taking chemotherapy alone.This is the first study to combine chemotherapy and immunotherapy both safely and effectively.A study to test vemurafenib in combination with Yervoy has already begun, according to HealthDay News.